FDA Approves Implant for Nearsightedness

Article

The FDA approved a corneal implant to correct near-sightedness.

The US Food and Drug Administration (FDA) today approved a device implanted in the cornea of one eye for some patients with presbyopia. It will not work if patients do not have clear distance vision.

It is the second FDA-approved implantable corneal device for correction of near-sightedness. It is meant only for patients who have not had cataract surgery, the FDA noted.

The devices is marketed as the Raindrop Near Vision Inlay. It is made by Revision Optics, Inc. of Lake Forest, CA.

The device is not for patients with severe dry eye, active eye infection, corneal disease characterized by general thinning and cone-shaped protrusion in the center of the cornea, and certain other conditions including uncontrolled diabetes.

The implant proved safe and effective in a clinical trial of 373 patients of whom 92% were able to see with 20/40 vision or better at near distances with the inlay.

According to the FDA, the implant could be an alternative to reading glasses or bifocals.

Related Videos
Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy| Image Credit: University of Chicago
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
© 2024 MJH Life Sciences

All rights reserved.